netFormulary Berkshire West NHS NHS
Royal Berkshire NHS Foundation Trust
Berkshire Healthcare NHS Foundation Trust
Berkshire West Clinical Commissioning Group
 
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
Notes:
This formulary is used by multiple organisations. There may be some instances where an item is on the formulary for one organisation but not the others. To help distinguish between each organisation, text will be colour coded, i.e. information relating to the Royal Berkshire NHS Foundation Trust will be in blue and Berkshire Healthcare NHS Foundation Trust will be in purple. Please ensure you read all information detailed under a drug.   
 Details...
02.03.02  Expand sub section  Drugs for arrhythmias
02.03.02  Expand sub section  Supraventricular arrhythmias
Adenosine (Adenocor)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Royal Berkshire NHS Foundation Trust >> Formulary Item injection / infusion (Adenoscan brand not available)  
   
Dronedarone (Multaq)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
Royal Berkshire NHS Foundation Trust >> Formulary Item as per NICE TA 197 (link below) ONLY  
Link  MHRA Oct 2011: Dronedarone (Multaq▼): cardiovascular, hepatic and pulmonary adverse events new restrictions and monitoring requirements
Link  NICE TA197: Atrial fibrillation - dronedarone
   
02.03.02  Expand sub section  Supraventricular and ventricular arrhythmias
02.03.02  Expand sub section  Ventricular arrhythmias
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Medicines that should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the primary care provider that the prescribing responsibility has been transferred. Where applicable, shared care protocols will be agreed and must be adhered to. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s)(DTC) and approved by Berkshire West APC.   

Brown

Drugs that have been reviewed and not recommended for prescribing. These drugs are not considered a cost effective use of scarce NHS resources. There may be individual patient specific or clinical reasons why a drug deemed low priority may be suitable for a particular patient. This is for the GP to condsider, weighing up the reasons against his/her allocated CCG budget. Where the decision is made to prescribe a low priority drug, detailed documentation must be included within the patients' notes for audit purposes. *Please note that low priority drug requests are unsuitable for the Case Review Committee and therefore should not be sent to this committee.   

Green

Medicines suitable for routine use and can be prescribed within primary care within their licensed indication in accordance with the BNF or other recognised national formulary. Primary care prescribers take full responsibility for prescribing  

Red

Medicines which should be prescribed by specialists only  

netFormulary